Clover Biopharmaceuticals Raises $230 Million
Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the company during the last year over USD 400 million. The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed, and existing investor Delos Capital.
Clover Biopharmaceuticals is a clinical-stage biotechnology company based in China. The company develops transformative biologics including vaccines and therapeutics for the world's most debilitating diseases.
The company plans to use the capital to expand its pipeline ...
